$\xi_{s}$孚


Date: Revised on January 18, 2006
Tcam Reviewer: Bonaventure Akinlosutu

EPA Reg. No. 2724-LNU
Registrant: Wellmark International
Product Manager: Gcorge LaRocca, PM13
Dec \# 355865
DP $\ddagger$ : 316838
Product Name: RF2004 (CCSO)
Active ingredient: $40 \%$ etofenprox and $3.6 \% 5$-methoprene
Formulation: RTU cat spot-on
Dose and application rate: 1.0 ml on cats under 5 lbs and 2.0 ml on cats 5 lbs or more.
Sites: cats

Pests: fleas, ticks and mosquitoes
OPPTS Guideline: 810.3300
GLP? Yes as indicated below.

Request: Evaluate efficacy data submitted in support of cat spot-on product performance claims. Efficacy data were not cited.

## Study Submitted:

MRID 46513410 Summary Report on RF2004 (CCSO) Development (non-GLP)
MRID 46513411 GLP Efficacy Against Adult Cat Fleas of Formulation RF2004 (CCSO) (GLP)
MRID 46513412 Efficacy Against cat Fleas of a RF2004(CCSO) Formulation.(non-GLP)
MRID 46513413 Efficacy Comparison Against Adult Cat Fleas of Sergeant's Gold Squeeze-On and a Variation of RF2004 (CCSO). (Non-GLP)
MRID 46513414 Efficacy Comparison Against Adult Cat Fleas of a Variation of RF2004
(CCSO) when Cats are Kept in Larger Enclosures. (non-GLP)
MRID 46513415 GLP Repellency and Efficacy Against Adult Mosquitoes and Ticks on cats of

Formulation RF2-004 (CCSO) (GLP).

## Summary of the Results from the Submitted Studies

The submitted data included non-GLP and GLP efficacy studies where in-vivo and in-vitro data were collected. The target dose of etofenprox was $231.1 \mathrm{mg} / \mathrm{kg}$ of cat. The effective product application rates were 1.0 to 3.0 ml per animal depending on the weight of the cat. The following table summarizes the submitted data:

| Pest | Method | Days of $90 \%$ or greater control | Etofenprox dose delivered per cat | Product <br> Application <br> Volume per Cat |
| :---: | :---: | :---: | :---: | :---: |
| Mosquitoes (Aedes and Culex spp.) | Caged in-vivo | 18 | 400 mg etofenprox per cat weighing under 9 lbs . ( 100 mg kg or more) and 600 mg efofcnprox per cat weighing 9 lbs or more ( 150 mg or less) | $\begin{aligned} & 1.0-1.5 \mathrm{ml} \\ & (0.9941 \mathrm{~g} \text { and } \\ & 1.49115 \mathrm{~g}) \end{aligned}$ |
| Black-logged tick | in-vitro with treated hair | $100 \%$ at day 7 $89 \%$ at day 32 | Same as for mosquitocs | Same as for mosquitoes |
| Amcrican dog tick | Caged in-vivo | 11 days | Same as for mosquitoes | Same as for mosquitoes |
| Adult Flea | in-vivo | 28 days --cagcd-- <br> 21 days --caged-- <br> 16 days --caged-- <br> 16 days --caged-- <br> 23 days penned - | $\begin{aligned} & 205 \mathrm{mg} / \mathrm{kg} \\ & 108-129 \mathrm{mg} / \mathrm{kg} \\ & 110 \mathrm{mg} / \mathrm{kg} \\ & 266 \mathrm{mg} / \mathrm{kg} \text { of } \\ & \text { etofenprox } \\ & \text { without product } \\ & \text { carrier } \\ & 266 \mathrm{mg} / \mathrm{kg} \text { of } \\ & \text { etofenprox } \\ & \text { without product } \\ & \text { carrier } \end{aligned}$ | $\begin{aligned} & 1.5-3.0 \mathrm{ml} \\ & 1.0-2.0 \mathrm{ml} \\ & 1.0-1.5 \mathrm{ml} \end{aligned}$ |

1. The dose for this study was expressed in terms of volume and the total number of grams applied per cat instead of being stated as mg of etofenprox per kg of cat. The values shown in the table are approximate calculations made by the EPA from the data.
2. Based on the density of the fommulation and concentration of the active ingredient, 1 ml of the formulation delivers 397 mg of etofenprox. 2.0 ml of formulation delivers 794 mg
of etofenprox. If the higher dose is reduced to 1.8 ml , the amount of etofenprox delivered would equal 714 mg .
3. In the study, half of the cats weighed $5-9 \mathrm{lbs}(2.27 \mathrm{~kg}-4.09 \mathrm{~kg})$ and the other half weighed 9 to 17 lbs ( $4.09 \mathrm{~kg}-7.73 \mathrm{~kg}$ ). This should have resulted is an ctofenprox dose range in the lower weight group of $176.6 \mathrm{mg} / \mathrm{kg}-97.7 \mathrm{mg} / \mathrm{kg}$ and in the higher weight group of $146.6 \mathrm{mg} / \mathrm{kg}-77.61 \mathrm{mg} / \mathrm{kg}$. Note that no cats below 5 lbs werc evaluated.
4. The average dose rate in the study groups was not stated. In the study tables summarizing the data for mosquito and tick testing there were 5 cats in each group. In the lower weight group the average weight was 7.8 lbs . or 3.54 kg yielding an average dose of etofenprox of $400 \mathrm{mg} / 3.54 \mathrm{~kg}=112.99 \mathrm{mg} / \mathrm{kg}$ of cat. In the higher weight group the avcrage weight was 9.98 lbs . or 4.53 kg yielding an average dose of $600 \mathrm{mg} / 4.53 \mathrm{~kg}=132.54 \mathrm{mg} / \mathrm{kg}$ of cat. Note that both these values are well below the target dose of 231 mg ctofenprox $/ \mathrm{kg}$ of cat. The 17 lbs cat was not listed in the results.
5. These data show that when cats are dosed at up to 132.54 mg of etofenprox $/ \mathrm{kg}$ of cat the product provides:
a. only 18 days of repellency protection against mosquitoes based on blood-fecding success of questing female mosquitoes exposed to cats;
b. 11 days of control against the American dog tick exposed to cats; and
c. in the in-vitro testing with Ixodes sp . (black-legged ticks) cxposed to treated cat hair (fur) $100 \%$ control at 24 hours post-exposure on day $7,50 \%$ control at 24 hours post-exposure on day 32 and $89 \%$ at 48 hours post exposure on day 32 . To achieve a higher degrec of efficacy more product is required per animal.
6. The registrant claims that the carrier in the formulation is tied to the residual efficacy of the product. Tests were conducted with and without the carrier and the carrier effect appears significant. Comparative testing also was donc with the registered Sergeant's product formulation containing $55 \%$ etofenprox. The subject product performed better than the registered product in these studics. Registrant claims it is due to the carricr but these results are not meaningful to the subject label claims.
7. For control of flea larva and eggs, at least 1.0 ml of product is required per animal as this is the lowest dose rate stated on 2724-488, a product with the same $\%$ of pyriproxifen.

## Entomologist's Recommendations

1. At 1.0 ml per cat, the subject product will deliver 397 mg of ctofenprox equivalent to a dose of ( $397 \mathrm{mg} / 0.45 \mathrm{~kg}=882 \mathrm{mg} / \mathrm{kg}$ ) $882 \mathrm{mg} / \mathrm{kg}$ when applied to a 1 lb cat and ( 397 $\mathrm{mg} / 2.23 \mathrm{~kg}=178 \mathrm{mg} / \mathrm{kg}) 178 \mathrm{mg} / \mathrm{kg}$ when applied to a 4.9 lbs . cat.
2. At $2.0 \mathrm{ml} /$ cat, the subject product will deliver $(714 \mathrm{mg} / 2.27 \mathrm{~kg}=314 \mathrm{mg} / \mathrm{kg}) 314 \mathrm{mg} / \mathrm{kg}$ to a 5 lbs cat and $157 \mathrm{mg} / \mathrm{kg}$ to a 10 lbs cat. For a 15 lbs cat, the dose would equal 104 $\mathrm{mg} / \mathrm{kg}$. NOTE: as a result flea control for cats over 10 lbs is likely to only be 3 weeks
based on the data showing that $205 \mathrm{mg} / \mathrm{kg}$ was necessary to achieve 28 day flea control.
3. The submitted efficacy testing for the subject product when applied according to draft label dircctions supports the following claims for mosquitoes: Repels mosquitoes for up to 18 days. From the draft label the following mosquito claims are acceptable:
"Direct on-animal protection for mosquitoes." Remove West Nile virus claims.
4. The submitted efficacy testing for the subject product when applied according to draft label directions supports label claims for black-legged ticks/decr ticks only of up to one-month. The label should be revised and refer to these ticks only. Lyme discase claims are acceptable. Rocky Mountain Spotted fever claims should be removed.
5. The submitted efficacy testing for the subject product when applied according to draft label directions supports the label claims for flca control up to one-month.
6. The reapplication interval of once per month supports the flca and black-legged tick claims only. Mosquito claims must be reduced to 18 days.
7. The acceptance of the above claims is based on the dose rates used in these studics and on the revised labeling. The $1.8 \mathrm{~m} /$ animal dose is supported as discussed above.
